{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:56:02Z","timestamp":1761947762428},"reference-count":42,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,11,22]],"date-time":"2011-11-22T00:00:00Z","timestamp":1321920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteolytic bone disease is a hallmark of symptomatic multiple myeloma. Bisphosphonates have been the mainstay of treatment to preserve skeletal integrity and prevent skeletal\u2010related events in patients with myeloma\u2010related bone disease. Recently, the MRC Myeloma IX trial demonstrated for the first time improved survival and delayed disease progression with the use of an intravenous amino\u2010bisphosphonate, zoledronic acid, vs. an oral agent, clodronate, with intensive and non\u2010intensive anti\u2010myeloma treatment regimens in patients with newly diagnosed multiple myeloma. These results validate a large body of preclinical, translational and other clinical data suggesting anti\u2010myeloma effects of amino\u2010bisphosphonates. In addition, this trial also provided the first head\u2010to\u2010head evidence for superiority of one bisphosphonate over another (zoledronic acid vs. clodronate) for reducing skeletal morbidity in patients with multiple myeloma, as well as a prospective comparison of toxicities. Despite the use of non\u2010bortezomib containing anti\u2010myeloma treatment regimens in the MRC Myeloma IX trial, these results are encouraging and provide an impetus to continue to evaluate current treatment guidelines for myeloma\u2010associated bone disease.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2011.01721.x","type":"journal-article","created":{"date-parts":[[2011,10,12]],"date-time":"2011-10-12T14:40:35Z","timestamp":1318430435000},"page":"1-7","source":"Crossref","is-referenced-by-count":5,"title":["The Medical Research Council Myeloma IX trial: the impact on treatment paradigms*"],"prefix":"10.1111","volume":"88","author":[{"given":"Paul G.","family":"Richardson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob P.","family":"Laubach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Schlossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantine S.","family":"Mitsiades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacalyn","family":"Rosenblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Mahindra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,11,22]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25516"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0603"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.291"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.3.733.733"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi235"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2009.12.002"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0525-7"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.1269"},{"key":"e_1_2_8_12_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. v.1.2012","author":"National Comprehensive Cancer Network","year":"2011"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60221-X"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.06.003"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.06.008"},{"key":"e_1_2_8_17_2","first-page":"867","article-title":"The IL\u20106 receptor super\u2010antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells","volume":"21","author":"Tassone P","year":"2002","journal-title":"Int J Oncol"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02983818"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401770"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.3.482"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03257.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00427.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24758"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05648.x"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02983531"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03824.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.384"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02698044"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23783"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62051-X"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02851.x"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.593"},{"key":"e_1_2_8_33_2","doi-asserted-by":"crossref","unstructured":"BerensonJ DimopoulosM ChenY\u2010M.Improved survival in patients with multiple myeloma and high BALP levels treated with zoledronic acid compared with pamidronate: univariate and multivariate models of hazard ratios. 48th ASH Annual Meeting and Exposition; 2006 December 9\u201312; Orlando FL. Abstract 3589.","DOI":"10.1182\/blood.V108.11.3589.3589"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022962"},{"key":"e_1_2_8_35_2","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma","volume":"3","author":"Mhaskar R","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_36_2","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1182\/blood.V116.21.3028.3028","article-title":"Comparative effectiveness of bisphoshonates in multiple myeloma [ASH abstract]","volume":"116","author":"Mhaskar R","year":"2010","journal-title":"Blood"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.10.019"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq259"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn796"},{"key":"e_1_2_8_40_2","volume-title":"Guidelines on the Diagnosis and Management of Multiple Myeloma","author":"Bird J","year":"2010"},{"key":"e_1_2_8_41_2","article-title":"A Canadian perspective on the use of bisphosphonates in the clinical management of multiple myeloma","author":"Reece D","journal-title":"New Evidence in Oncology"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62178-2"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-6-664"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2011.01721.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2011.01721.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/j.1600-0609.2011.01721.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2011.01721.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T23:27:28Z","timestamp":1698708448000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2011.01721.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,22]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1111\/j.1600-0609.2011.01721.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01721.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,22]]}}}